Summary.-Potential anti-cancer agents have classically undergone clinical assessment in Phase I, II and III trials. This paper examines the role of these trials and preclinical studies in the light of improving cancer chemotherapy. Many patients must now be treated with standard therapy before investigational drugs can be ethically used. The introduction of combined modality trials will require a very prolonged follow-up to demonstrate improved survival and recognize late onset of chronic toxicity.
CANCER chemotherapy has made many advances in the treatment of malignant diseases. It is paradoxical that the often dramatic improvements in the treatment of these patients have now led to our present difficulties in the development of new agents.
In the 25 years since the National Cancer Institute modified the FDAderived Phase I, II and III trials it has often become difficult to test new drugs, as they may only ethically be given to patients who have failed standard therapy.
At the time that these methods came into use, drug trials were simple clinical experiments in which some evidence of activity as a single agent was the end point. Most drugs tested showed low or moderate levels of activity, producing only minimal clinical responses. However, drugs are now combined so that they are more effective and are capable of producing frequent good responses and complete remissions in a number of tumours.
These improvements in chemotherapy have frequently made it difficult to test new drugs adequately. Many of the patients who can ethically be used in Phase I and II clinical trials are of low performance status, having received previous chemotherapy and/or radiotherapy, and are the patients who could be least expected to respond to further treatment. Thus, as we improve chemotherapy, it will become more difficult to test new drugs or analogues of existing ones, as many patients must be given standard treatment before we can ethically embark on treatments of unknown efficacy.
The situation is further complicated by the introduction of combined-modality therapy which includes chemotherapy. Though the methodology of such trials is still being worked out, it is already clear that these trials will be a major undertaking, requiring prolonged follow-up of patients for 10-20 years, if we are to learn the true impact of treatment on survival and the incidence of chronic or late-onset complications.
Preclinical studies
Preclinical studies are performed in various animals and in vitro systems to assess the potential activity and toxicity of new drugs. While these studies are important in the selection of potentially active agents it is the results of Phase I and II trials that determine whether a new drug will be fully assessed for clinical use.
Experimental models
The use of experimental models in the selection of "active" compounds introduces many problems, the major of those being the selection of model test systems which are able to identify compounds with a high likelihood of clinical activity, (Carter, 1973) . Although all systems are capable of producing true or false positives and negatives, it is not possible to know the false negative rate in present experimental models, as drugs which are negative never come to clinical trial.
All screening programmes must involve compromise, and it is clear that some compounds which would be clinically active are not detected by the present model systems and never reach clinical trial.
Owing to the logistic problem of testing large numbers of compounds of unknown efficacy in potential new model systems, it has been the policy of most centres working in this field only to use drugs of known efficacy in the detection of new model systems. Unfortunately, these particular drugs will have been identified by present systems which will have missed potentially active drugs. Thus, new systems will tend to mimic systems already in use, and may also fail to identify those "active" drugs missed by present systems.
Fortunately, compounds of known activity were not predicted by one system, and this provides a heterogeneity that can be used in evaluating new model systems. For example, Fig. 1 illustrates an approach which tests a new system against a number of drugs found to be active in L1210 and an equal number of drugs inactive in L1210, but active in other predictive models. The new system would be highly desirable if it showed activity by all the L1 210-inactive drugs (even if it indicated lack of activity for the L12 10-active drugs). The opposite result would be unattractive as it would only mimic the L1210 system. Most systems fall between these two 
Toxicity
The extrapolation of data from animal to man poses many difficulties, though we have learned to predict toxicity in man with reasonable accuracy. Studies (Owens, 1962; Schein, Davies and Cooney, 1973) retrospectively comparing toxicities in animal species and man have shown that human toxicities in the haematopoietic, gastro-intestinal, renal and hepatic systems can generally be predicted from data collected in animals. However, in the two most commonly used large animal species (dog and monkey) there is a tendency to over-predict toxicity, especially in the renal and hepatic systems. In many animals, organ system toxicities are obtained at severely toxic and lethal doses. This may account for some of the overprediction, since drugs are not given at such high levels in man.
Skin, cardiac and peripheral-nervoussystem toxicity are not well predicted, and the detection of central-nervous-system toxicity is dependent on the care with which animals are assessed neurologically.
Specific parameters of toxicity, such as leucopenia in the haematopoietic system, are less accurately predicted than broad organ toxicities. Thus, anaemia may be the predominant haematopoietic toxicity in animals, whilst leucopenia may predominate in man.
A number of studies (Freireich et al., 1976 , Homan, 1972 Pinkel, 1958) (1976) suggested that one-third of the maximum tolerated dose defined by the weighted estimate of 5 animal species (in mg/M2) would be a safe starting dose for most chemotherapy trials. However, Homan (1972) In the most recent analysis of this type (Goldsmith, Slavik and Carter, 1975) When new anticancer agents are first administered in patients, there is frequently a lack of relevant data to suggest safe methods of setting up the study. Ideally, before beginning a Phase I study the following information should be available:
(1) A method (preferably chemical) of measuring the compound in blood or other body fluids.
(2) A knowledge of blood levels achieved by single, multiple and infusion techniques of administration in several animal species.
(3) A knowledge of the blood level of the compound in relation to toxicity and therapeutic action.
(4) The pharmacology of the drug should be known in animal species, so that the methods of administration and study of human pharmacology are optimal.
All too frequently, drugs go into clinical trials without this information available. A question which has caused a great deal of debate among medical oncologists is whether a Phase I clinical trial of a new drug should be deferred until the pharmacological methodology has been developed. This could delay clinical studies for a long time. On the other hand, premature clinical assessment may run the risk of missing good drugs because they have been given in an inappropriate schedule, perhaps producing unnecessary toxicity.
Dose escalation.-One of the most critical steps in setting up a Phase I study is deciding on a starting dose and a method of dose escalation which allows the maximum tolerated dose (MTD) to be reached safely and efficiently. One of the more common methods used is the modified Fibonacci search scheme (Hansen et al., 1971) which employs a fixed series of dose escalations with decreasing increments. In the absence of toxicity the dose escalations continue according to the scheme. However, when mild but reproducible toxicity is encountered, the escalation is reduced to the 30-35% level until the MTD is established. It has been estimated that this method would require 5 (±3) dose escalations for most drugs. Goldsmith et al. (1975) increments and decreased to 25% increments when toxicity was encountered. Gold (1962) has proposed a geometric progression of dose escalations, starting at 1/100 the rodent LD50, but with its progressively increasing doses per escalation this method would probably result in excessive toxicity for most compounds.
Currently, no statistical model for dose escalation is inherently safe and efficient for all drugs. Most investigators begin with large increments (rarely more than two-fold) when no toxicity is seen, and decrease the escalations when minimal toxicity is encountered. Currently, it is the opinion of many workers that it is safe to continue to double the dose as long as no toxicity has been observed at the previous level.
Dose escalation methods have not taken into account blood levels of the compound and correlated this with the toxicity associated with similar levels in animal models. Such techniques might allow safer and more efficient dose escalation, should a reproducible correlation exist between toxicity and blood levels in human and animal models.
In most trials, 3 patients are placed on the initial dose and adequate time is allowed for follow-up of delayed toxicity before entering patients on the next dose. As toxicity is encountered, more patients are entered at each dose level until the MTD is reached. Many investigators feel that doses should not be escalated in individual patients, as it becomes impos-sible to know whether a toxic effect is the result of the cumulative dose or the administered dose.
The goal of a Phase I study is to find the MTD for a particular drug schedule. In practice the MTD achieved in any trial is a function of the degree of prior therapy to which the patients have been exposed and their performance status. Patients of low performance status who have received extensive prior chemotherapy or radiation therapy, will have less tolerance for further chemotherapy. However, in the experience of the authors there have been no cases where the MTD derived in a Phase I study has been increased by a subsequent Phase II study. This may be related to the expertise and support facilities available to those who conduct Phase I studies, and to the natural caution of investigators in Phase II and III studies.
Phase I studies have essentially been trials of toxicity, the end point being the identification of the MTD. These studies are also an ideal opportunity to gather pharmacokinetic data. If these data are collected, then selection of dose schedules and methods of reducing toxicity could be the result of intelligent use of the data rather than the use of routine screening procedures. Greater care in trial design, and more attention to the pharmacokinetic data gained in preclinical and Phase I studies, might allow more rational choice of dose and schedule regimes, rather than using blind screening systems. Phase II studies comparing various dose and schedule regimes would undoubtedly be more complex, requiring some of the mechanisms previously employed in Phase III studies. However, deciding on the dose and schedule is clearly a very important step in the development of a new drug, and deserves to be treated in a less cavalier fashion than at present.
On the completion of a Phase II study a reasonable estimate of the efficacy of the drug used in a particular dose schedule should be available. In addition, further more definitive information on drug toxicities should be available. The decision to continue drug development in a Phase III study will be made on this data, which can be treated as a risk-benefit ratio.
Tumour-orientated trials.-When efficiency is the criterion for the advisability for further trials, Gehan and Schneiderman (1973) have pointed out that the decision to be reached is whether or not an agent can be effective in x% of patients or more.
The answer can usually be reached in a relatively small number of patients. The value of x % will vary according to the efficacy of drugs that are already available for the treatment of a particular tumour, and in non-randomized studies the appro-priate value of x is usually subject to some uncertainty.
The original type of Phase II study, using a large number of patients with tumours of many differing types, is probably no longer applicable. Survival may also be used as an end point in Phase II studies when life expectancy is very short. Survival, however, is a much more stringent criterion than tumour response, and a majority of patients with increased survival will be needed to improve a median survival, so that only particularly active drugs will be identified.
Study design.-The role of known prognostic factors in a randomized study design has already been discussed. A relatively large number of patients must be entered into a study, so that random (and, we hope, equal) distribution of known and unknown prognostic factors occurs. It is possible by "stratification" to ensure that the known important prognostic factors are evenly distributed within "stratum" in a trial. Simple randomization would not necessarily ensure equal distribution of known prognostic factors, particularly in relatively small trials such as most Phase II studies, though it may be possible to allow for this when the data are analysed (Peto et al., 1976 (Peto et al., , 1977 .
In a non-randomized Phase II study, all patients are given a single treatment. The study should be designed in such a way that known prognostic factors are recorded for each new patient admitted. Thus, patients of poor performance status after multiple chemotherapy and radiation therapy can be analysed separately from newly diagnosed patients of good performance status. However, there may still remain some uncertainty about the interpretation of such studies, for the "expected" outcome in a particular group of patients can never be predicted exactly.
The study design, and patients accrued to a trial, depends very much on the tumour being studied. There are basically 4 groups of patients with cancer available for study, each defined by its responsiveness to other chemotherapies (Table II) . (Fig. 3, Plan C) . They could also be studied in a consecutive non-randomized manner in relatively good-risk patients, again with the extra uncertainties in non-randomized treatment comparisons.
The 4 groups of tumours, as defined by responsiveness to present drugs, are fluid and, as chemotherapy improves, most patients will fall into the group where we already have highly effective treatment, and where Phase 11 studies only become ethical when the patient is least likely to respond to further drug therapy. We are, therefore, going to require new and more sensitive methods of detecting the therapeutic potential of new drugs. Whether in vitro tumour-cell-culture assays, or assays using tumours transplanted into nude mice, will be of use remains unanswered. However, it is clear that only drugs which are highly active will be detected by present methods in patients with advanced disease which is resistant to current therapy. However, it must be remembered that only such drugs will be required, if effective treatment is already available. The detection of equally active but less toxic drugs will, however, remain a problem.
Phase III Trials
Phase III trials are an attempt to determine the role of a new drug in the practice of oncology. These studies are, therefore, complex and require good data collection and quality control. Classically, a Phase III study tests a new drug against a standard agent, but the present emphasis on disease-orientated trials may mean that a new drug often enters Phase III in combination with other standard agents.
Stratification. Simple randomization does not guarantee an equal balance of all important known prognostic variables between treatment groups. Though stratification, prior to randomization, has frequently been employed to ensure a balance of prognostic factors between groups, many statisticians (Peto et al., 1976 (Peto et al., , 1977 now agree that the benefits of this method are not great, as long as appropriate modern methods of statistical analysis are used.
The main advantages of pre-randomization stratification are apparent in very small trials. Stratification at entry will ensure a reasonable balance of patients receiving each treatment and will avoid a situation in which almost all the patients in one retrospective stratum get the same treatment. Such a situation is likely to arise only in a very small trial.
Control groups.-The control groups in clinical trials have been of 2 basic types: (1) patients treated concurrently and randomly assigned to this group, and (2) those selected from past records and termed "historical controls".
It has been suggested (Gehan and Schneiderman, 1973; Gehan and Freireich, 1974; Farber, 1966 ) that careful selection of controls from the literature, matched controls from a particular group or institution, or controls from sequential studies, may provide an adequate group for comparison with a new therapy. This has not proved to be so. Selection of comparable controls requires an attempt at balancing known prognostic factors and, as Schneiderman pointed out, the use of historical controls almost assumes that you know all you will need to know about what determines responses in patients. This is hardly ever true; new prognostic variables are constantly being uncovered or rediscovered. The introduction of tumour markers and immunological tests will continue to provide further information on prognostic variables. Not only are prognostic variables improperly understood; many Phase II studies are performed without attempts to "match" the historical control. Use of historical controls can also be questioned because apparent improvement observed with a new therapy may be due to poorly understood factors, such as:
(1) Patients presenting earlier for diagnosis and treatment at University centres, and when treatment is thought more likely to be successful.
(2) Improved ancillary care, which may allow a better response rate.
(3) Improvement of physicians' expertise with time and greater enthusiasm about the current study. 
Study design
Once the type of trial to be undertaken has been decided, a protocol must be written. A protocol should ideally outline the rationale for the study and then give strict guidelines for admission criteria and exclusion. Most protocols involve selection of specific patients by various factors (i.e. age, stage, performance status). The outcome of the study is, therefore, related to these particular patients treated in a specific manner. Every study involves the following sequential flow of patient numbers:
(1) Number evaluated for entrance into the study, i.e. all patients with the disease type and stage to be studied.
(2) Number eligible for entrance into the study, i.e. those patients who fit the specific criteria for admission into the study within the disease type and stage.
(3) Number entered. (4) Number evaluable, i.e. those patients who have received the number of treatment courses specified by the protocol. Later exclusion of the non-evaluable patients is often an error.
The denominator used in determining response frequently becomes progressively smaller, from those considered for entrance to those "adequately treated". There must therefore be careful presentation and analysis of all patients considered non-evaluable or inadequately treated. Specific instructions regarding patients whose treatment deviates from the protocol or who withdraw from the trial should be written into the protocol; it is not adequate to decide at the end of a trial how these patients should be analysed. Exclusions do not bias a study, as these patients are not entered into the study, but withdrawals, e.g. of nonevaluable patients can bias a study. For example, only those patients who are well enough might contemplate leaving a study, and would thus have a negative effect on the results. Attempts should be made to follow-up all patients even if they withdraw from the study.
Care should also be exercised when there is doubt about the diagnosis. This may be solved by not randomizing until the diagnosis is unequivocal, or by randomizing all patients in whom the diagnosis is in doubt and by including all patients in the analysis, regardless of their final diagnosis. Alternatively, all patients could be randomized, and those patients in whom the diagnosis is changed could then be excluded from the analysis. This might be more appropriate when blind review is undertaken by a critical review board, and may be advantageous if review is undertaken at the end of the trial, as there will be greater uniformity in interpreting histopathology. Treatment deviations from the protocol should not be excluded from analysis, as this may seriously bias the result. If these patients are excluded, this should be stated and included in the analysis of the study.
The exclusion of pre-treatment or earlytreatment deaths in a treatment group may also seriously bias the trial, and should be avoided, especially when there is an untreated control group. If early deaths are excluded from analysis, severe drug-related toxicity may be ignored and an unwarranted favourable result reported. A clinical trial is a study of a group of patients as defined by the entry criteria. If this group includes some early deaths, then they should be included in analysis; patients unlikely to die early could, if desired, have been selected by different entry criteria.
It is very important to have an estimate of the number of patients required to answer the question posed by the study. This is more related to the number of patients reaching the end point of the study, i.e. relapse or death, than to the total number entering to the study. Peto et cl. (1976 Peto et cl. ( , 1977 and an outline of the protocol. The achievement of a significant P-value is not the aim of a trial, and excessive reliance on P will be misleading in some cases. A P-value is only of importance if it can be demonstrated that the trial has been run in such a way that statistical analysis is valid, which is usually so in a randomized prospective study undertaken with scrupulous care. The achievement of particular P-value in a trial will, of course, be interpreted in the light of a clinician's experiences and perhaps prejudices (Peto and Doll, 1977) .
For further details on the analysis of clinical trials, Peto et al. (1976 Peto et al. ( , 1977 provide guidance and many examples in the second part of their paper.
Combined modality trials
It is only very recently that combined modality approaches to cancer have become more commonly used. Paediatric oncology has shown that such an approach can be successful in Wilms' Tumour (Sutow et al., 1970; Sullivan and Sutow, 1969) embryonal rhabdomyosarcoma (Pratt et al., 1972; Pinkel and Pratt, 1] 973) and Ewing's sarcoma. Adult oncologists are now exploring combined modality approaches in adult cancer with some early successes in breast cancer (Fisher et al., 1975 , Bonadonna et al., 1976 If disseminated disease does exist, systemic therapy is required to control disease elsewhere in the body. Therapeutic modalities with this potential include chemotherapy, immunotherapy, whole-body irradiation and endocrine manipulation. Chemotherapy is undoubtedly the most active of these modalities available, with a known ability to produce remissions and "cures" in some cancers when either single drugs or combinations are used.
Chemotherapy has been shown experimentally to be most effective when the tumour burden is low and kills by firstorder kinetics (fixed percentage kill) so that, when the tumour burden is low, total cell kill may occur with a reasonable number of repetitive doses before resistance can develop.
The degree of drug activity which is required in advanced disease for therapy to be successful in an adjuvant study is not known. Currently it is assumed that drugs or combinations of drugs which are capable of objective responses (500 reduction in tumour mass) in advanced disease will be capable of total cell kill when used for residual disease after local modality therapy. The level of activity (complete or partial remission rate) required is not known. It is encouraging that L-PAM (Fisher et al., 1975 ) with a 20% objective remission rate has achieved some preliminary success in Stage II breast cancer when used as an adjuvant. However, 5-fluorouracil (Carter, 1976) has apparently not been of use as an adjuvant in large bowel cancer, despite a similar objective response rate. Explanations for such differences include variation in residual tumour burden, cell kinetics and drug availability at a tumour cell site.
Trials designed to examine the role of combined modality and adjuvant treatment should always be randomized prospective controlled studies. The mechanisms used in Phase III studies will need to be applied. Large numbers of patients will be required to demonstrate relatively small but important (10%) gains in survival. Long-term follow-up will be required to accurately assess any improvement in survival rates (early reporting of data may give a spurious impression as delay in recurrent disease and not "cure" may result). It is possible that adjuvant therapy may compromise the ability to palliate patients after tumour recurrence, so that there is little overall impact on survival.
Long-term follow-up is also required to ensure that chronic and late-onset toxicity are adequately assessed. The incidence of second malignancies following combined radiation and chemotherapy is unknown, though it is clear that the leukaemia incidence is increased (Williams et al., 1977) .
Combined modality trials not only need stringent design in order to produce valid results; they will require that we set up accurate methods of long-term data collection and close patient follow-up. The longterm collection of data is aided in the United Kingdom by the Office of Population Census and Surveys. By prior arrangement they will, if given the full names and exact dates of birth of all trial patients, notify the trial organizer whenever any deaths occur, giving the date and certified cause of death and name of physician who certified the death. Adequate follow-up of survival is thus made much easier in Britain than many other countries. 
